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Background: Histone deacetylases (HDACs) play a critical role in the maintenance of genome stability. Class I
HDACs, histone deacetylase 1 and 2 (Hdac1 and Hdac2) are recruited to the replication fork by virtue of their
interactions with the replication machinery. However, functions for Hdac1 and Hdac2 (Hdacs1,2) in DNA replication
are not fully understood.
Results: Using genetic knockdown systems and novel Hdacs1,2-selective inhibitors, we found that loss of Hdacs1,2
leads to a reduction in the replication fork velocity, and an increase in replication stress response culminating in
DNA damage. These observed defects are due to a direct role for Hdacs1,2 in DNA replication, as transcription of
genes involved in replication was not affected in the absence of Hdacs1,2. We found that loss of Hdacs1,2 functions
increases histone acetylation (ac) on chromatin in S-phase cells and affects nascent chromatin structure, as
evidenced by the altered sensitivity of newly synthesized DNA to nuclease digestion. Specifically, H4K16ac, a
histone modification involved in chromatin decompaction, is increased on nascent chromatin upon abolishing
Hdacs1,2 activities. It was previously shown that H4K16ac interferes with the functions of SMARCA5, an ATP-
dependent ISWI family chromatin remodeler. We found SMARCA5 also associates with nascent DNA and loss of
SMARCA5 decreases replication fork velocity similar to the loss or inhibition of Hdacs1,2.
Conclusions: Our studies reveal important roles for Hdacs1,2 in nascent chromatin structure maintenance and
regulation of SMARCA5 chromatin-remodeler function, which together are required for proper replication fork
progression and genome stability in S-phase.
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Histone deacetylase inhibitors (HDAC inhibitors/HDIs) are
potent anticancer drugs. Several broad-spectrum inhibitors
are in various stages of clinical trials for both solid tumors
and hematopoietic malignancies [1]. Two of these com-
pounds (SAHA/Vorinostat and Depsipeptide/Romidepsin)
have gained FDA approval for their use against T-cell cuta-
neous lymphomas. SAHA and Depsipeptide target class I
HDACs (Hdacs 1, 2, 3 and 8) [2]. Therefore, it is imperative
to study and understand the specific functions of individual
HDACs in order to ascertain drug specificity and design* Correspondence: srividya.bhaskara@hci.utah.edu
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reproduction in any medium, provided the ortargeted therapeutics with increased potency and minimal
side effects.
Hdac1 and Hdac2 are the core enzymes in three distinct
protein complexes (Sin3, NURD and CoREST) that have
diverse cellular functions [3]. Targeted deletion of Hdac1
led to embryonic lethality [4]. Hdac2-null pups die within
a month due to cardiac defects and abnormalities in
myocyte proliferation [5]. Knockout of either Hdac1 or
Hdac2 had minimal effect on hematopoiesis and on the
cell cycle, likely due to compensation for one by the other,
as they are highly similar proteins. However, deletion of
both genes dramatically impaired proliferation in multiple
cell types by blocking cells at the G1 to S phase transition
[6,7]. Additionally, double knockout of these enzymes
caused mitotic catastrophe in fibrosarcoma cells [8]. While
a role for HDACs in transcription is well established
[9-11], these enzymes also function in DNA replication.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(PCNA, a DNA replication processivity factor) [12]. Also,
Hdacs1,2 associate with newly replicated DNA [13]. How-
ever, the precise functions for Hdacs1,2 in DNA replica-
tion are still not fully understood. Broad-spectrum (‘pan’)
HDAC inhibitors inhibit cell cycle progression and kill
cancer cells by triggering DNA damage during DNA repli-
cation/S-phase [14]. Hence, it is important to understand
how Hdacs1,2 function during replication and how these
HDACs affect nascent chromatin.
In this study, we aimed to understand the mechanistic
roles for Hdacs1,2 in DNA replication. Using novel selective
inhibitors and genetic knockdown systems, we show that
Hdacs1,2 functions are required for the proper progression
of the DNA replication fork, and loss of Hdacs1,2 activities
leads to the activation of replication stress and DNA damage
response. This defect in replication is not simply caused by
changes in transcription, as gene expression for factors in-
volved in replication remain unchanged following Hdacs1,2-
inhibitor treatment. Mechanistically, the defect in replication
in the absence of Hdacs1,2 functions can be attributed to an
altered chromatin structure, due to increased histone acetyl-
ation on S-phase chromatin, especially increased H4K12ac
and H4K16ac levels. H4K12ac and H4K16ac antagonize
substrate recognition and nucleosome remodeling activity of
SMARCA5, an ISWI family chromatin remodeler [15,16].
In this study, we further show that SMARCA5 is present on
nascent chromatin, and loss of SMARCA5 also leads to a
decrease in the replication fork velocity and activation of the
replication stress response. This demonstrates an important
role for SMARCA5 in replication fork progression in mam-
malian cells. Overall, we provide a model wherein Hdacs1,2
affect DNA replication fork progression by regulating his-
tone acetylation on nascent chromatin and SMARCA5
activity.
Results
Abrogating histone deacetylase 1 and 2 activities
increases replication-associated histone deposition marks
Both Hdac1 and Hdac2 localize to sites of DNA replica-
tion [13]. In HEK293 cells, Hdac1 interacts with PCNA,
the replication-sliding clamp [12]. We sought to test
whether Hdac2 also interacts with PCNA in human cells
using co-immunoprecipitation. Hence, we used human
HeLa cell extracts for this analysis. Indeed, we find that
both Hdac1 and Hdac2 co-immunoprecipitate with PCNA
(Figure 1A). We next examined whether Hdacs1,2 associ-
ate with replication origins in cells synchronized in S-
phase. Given the efficiency of cell synchronization by
serum-starvation and to obviate the need to use any
chemical cell cycle blocking agents, we employed NIH3T3
cells for further experiments. NIH3T3 cells were serum-
starved to arrest cells in the G0/G1 phase of the cell cycle.
Cells were then released into S-phase by growing them ina serum-rich medium for various time points (12 h, 18 h,
24 h). Using chromatin immunoprecipitation (ChIP) as-
says, we found that Hdac1 and Hdac2 are enriched at can-
didate early (α-globin), mid-late (pancreatic amylase) and
late (β-globin) replicating loci in cells synchronized in S-
phase [17] (Figure 1B and Additional file 1: Figures S1A
and S1B). Collectively, our findings confirm that Hdacs1,2
interact with PCNA and localize to sites of DNA replication.
Newly synthesized histones are acetylated on histone H4 K5
and K12 residues prior to their deposition onto nascent
chromatin, and are then removed during chromatin matur-
ation [18]. One function for Hdacs1,2 during DNA replica-
tion might be to deacetylate these histone deposition marks.
In primary mouse embryo fibroblasts (MEFs), deletion of
Hdac1 and 2 leads to an increase in H4K5ac and H4K12ac
[7]. We examined the global levels of H4K5ac and H4K12ac
in nuclear extracts prepared from cells following siRNA-
mediated knockdown of Hdacs1,2 in NIH3T3 cells. We also
examined H3K9,K14ac, a mark associated with transcription
[19,20]. Knockdown of both Hdacs1,2 led to an increase in
H4K5ac, H4K12ac and H3K9,K14ac in NIH3T3 cells when
compared to the control cells transfected with non-targeting
siRNA (Figure 1C). In corroboration with previous studies
in primary cells [7], deletion of Hdac1 alone or knockdown
of Hdac2 alone in fibrosarcoma cells did not result in any
increase in H4K5ac (Additional file 2: Figure S2). Therefore,
both Hdac1 and Hdac2 target the histone deposition marks.
To further examine if histone acetylation marks in-
crease upon inhibition of Hdacs1,2 activities, we chose
to selectively inactivate these two enzymes using novel,
benzymilic class small molecule inhibitors (RGFP898
and RGFP233, henceforth referred to as 898 and 233, re-
spectively). We first determined the selectivity of these
two molecules towards Hdacs1,2. The IC50 values
obtained using in vitro HDAC assays showed 233 and
898 inhibit Hdacs1,2 activities at a low concentration
(Additional file 3: Figure S3A). Unlike SAHA, the inhibi-
tory activity of RGFP106 (another benzamide-type in-
hibitor similar to 898 or 233) was previously shown to
remain unchanged even after 100-fold dilution of the
inhibitor-enzyme mixture and histone acetylation did
not return to basal levels even after washing away the in-
hibitor [21]. Therefore, these benzamide-type Hdacs1,2
inhibitors are slow and tight-binding compounds. We
next examined the efficacy of 898 and 233 to inhibit
Hdacs1,2 in NIH3T3 cells. An increase in histone acetyl-
ation was observed following treatment of NIH3T3 cells
with 2 to 10 μM 898 (Additional file 3: Figure S3B). We
then determined the minimum concentration range re-
quired to inhibit Hdac1,2 activities and to increase his-
tone acetylation in NIH3T3 cells. A robust inhibition of
only Hdacs1,2 activities was observed at lower concen-
trations of 898 or 233 (3.0 to 3.75 μM) (Figure 1D, 1E).
To ensure the reduced enzyme activity is not due to
Figure 1 Histone deacetylase 1 and 2 (Hdacs1,2) localize to replication origins and target histone deposition marks. A. Western blot
analysis of immunoprecipitated (IP) samples to determine interaction of Hdac1 and Hdac2 with proliferating cell nuclear antigen (PCNA). Nuclear
extracts from HeLa cells were used in IP with anti-PCNA antibody or IgG (negative control). Percentage ratio of IP over input for Hdac1 and
Hdac2 are shown. B. Hdac1 and Hdac2 occupancies at α-globin locus (early replicating origin) in NIH3T3 cells synchronized in S-phase were
determined using chromatin immunoprecipitation (ChIP) assays. Average fold enrichment of immunoprecipitated DNA over input DNA from
three independent experiments is shown. C. Western analysis of nuclear extracts prepared from NIH3T3 cells transfected with either non-targeting
(NT) or Hdac1,2 siRNA (H12si) at 72 h post-siRNA transfection to determine changes in histone modifications. D-E. Hdac1 or Hdac2 or Hdac3
immunoprecipitated from nuclear extracts following treatment of NIH3T3 cells with either DMSO (D), 898 (panel D) or 233 (panel E) were used in
enzyme assays. Enzyme inhibition was measured using Fluor-de-Lys HDAC fluorimetric activity assay. AFU, arbitrary fluorescence units; dotted line,
denotes background/baseline signal obtained from using rabbit IgG in IP. F-G. Western analysis to determine changes in histone acetylation in
NIH3T3 cells following 24 h treatment with DMSO or increasing concentrations of 898 (F) or 233 (G). H-I. Western analysis of whole cell lysates
prepared from Hdac1Fl/FlHdac2Fl/Fl or Hdac3Fl/Fl fibrosarcoma cells following Ad-Cre infection and treatment with 898 or 233. Cells were treated
with 3 μM 898 or 233 for 24 h following a 48 hr Ad-Cre infection.
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assay, we checked and confirmed that, indeed, equal
amount of Hdac1, Hdac2 and Hdac3 were present in theimmunoprecipitates (Additional file 4: Figure S4). Col-
lectively, these characterization studies confirmed the ef-
ficacy of 898 and 233 as Hdac1,2-selective inhibitors,
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range for these two inhibitors to be used in our studies
(3 to 3.75 μM).
Similar to the knockdown of Hdacs1,2 (Figure 1C), in-
hibition of Hdacs1,2 in vivo using the selective inhibitors
(898 or 233) also resulted in an increase in H4K5ac,
H4K12ac and H3K9,K14ac levels when compared to cells
treated with vehicle alone (DMSO) (Figure 1F-G). Given
their high sequence homology [22,23], we sought to further
confirm the specificity of 233 and 898 towards only
Hdacs1,2 and not Hdac3. To this end, we used fibrosar-
coma cells containing floxed alleles of either Hdac1 and
Hdac2 (Hdac1Fl/FlHdac2Fl/Fl) or Hdac3 (Hdac3Fl/Fl) to ob-
tain conditional knockout of these enzymes upon express-
ing Cre recombinase [8]. Efficient depletion of Hdacs1,2
and Hdac3 were observed in these cells following infection
with an adenovirus-containing Cre recombinase (Ad-Cre)
(Figure 1H and 1I). Conditional deletion of Hdacs1,2 in
fibrosarcoma cells led to a significant increase in H4K5ac
(Figure 1H), whereas deletion of Hdac3 led to a subtle in-
crease in H4K5ac (Figure 1I). Treatment of Hdac1,2
knockout cells with 233 or 898 did not result in any further
increase in H4K5ac (Figure 1H, Additional file 5:
Figure S5A and S5B), confirming that these two inhibi-
tors are selective for Hdacs1,2. Addition of 233 or 898 to
Hdac3 knockout cells resulted in a significant increase in
H4K5ac (Figure 1I). This increase in H4K5ac is an additive
effect obtained due to the inhibition of Hdacs1,2 activities
by these two molecules combined with the loss of Hdac3
activity (Figure 1I and Additional file 5: Figures S5C
and S5D). Taken together, our studies using genetic sys-
tems and selective inhibitors reveal a role for Hdacs1,2 in
the removal of histone deposition marks.
Inhibition of histone deacetylase 1 and 2 activities does
not affect the progression of cells through S-phase, but
decreases bromodeoxyuridine incorporation
Deletion of both Hdac1 and Hdac2 in primary mouse
embryo fibroblasts using a tamoxifen-inducible condi-
tional knockout system resulted in G1 arrest and a dra-
matic decrease in BrdU incorporation, as cells failed to
enter and progress through the S-phase [6,7]. However,
these phenotypes are evident only following progression
of knockout cells through a few rounds of the cell cycle
[6,7]. The G1 arrest caused upon abrogation of Hdacs1,2
functions has restricted studying the functions for these
two enzymes within S-phase and in DNA replication.
However, treatment of NIH3T3 cells with 898 or 233
did not arrest cells in G1 phase following 24 h treatment
(Additional file 6: Figure S6A-B). Therefore, we serum-
starved cells to induce G0/G1 arrest. Cells were then re-
leased into S-phase by growing them in a serum-rich
medium supplemented with either vehicle (DMSO) or
the Hdacs1,2-selective inhibitor (898 or 233) and treatedfor various time (12 h, 18 h, 24 h). S-phase cells were mea-
sured by fluorescence-activated cell sorting (FACS) ana-
lysis following BrdU and propidium iodide staining. We
did not observe any accumulation of cells, indicative of a
block within S-phase, at the three different time points of
treatment with 898 (Figure 2A). We did not observe G1
arrest in NIH3T3 cells transfected with Hdacs1,2 siRNAs
at 72 h post-transfection, even though we observed in-
creased histone acetylation at this time point (Additional
file 6: Figure S6C). Additionally, treatment with 3 μM 898
or 233 did not affect the progression of cells from G1 to
early S-phase (12 h post-release), early to mid S-phase (18
h post-release) and mid- to late S-phase-G2/M (24 h post-
release) (Figure 2A and Additional file 7: Figure S7).
Continuous inhibition of Hdac1,2 activities with 898 for
48 h in NIH3T3 cells led to a G1 arrest of cells and de-
crease in S-phase population (Additional file 8: Figure S8).
Hence, the availability of small molecule inhibitors (898 or
233) and treatment of cells for short duration (12 to 24 h)
allowed us to selectively inhibit Hdacs1,2 within S-phase
cells and test whether inhibition of Hdacs1,2 affects pro-
gression of cells through the S-phase. Importantly, these
findings provided us a window to study Hdacs1,2 func-
tions within S-phase following their inhibition using a
selective inhibitor (12 to 24 h) or the knockdown system
(72 h).
To examine if Hdacs1,2 activities are required for
DNA replication, we released serum-starved cells into
S-phase and treated them for 12 h, 18 h or 24 h with ei-
ther the vehicle (DMSO) or the Hdac1,2-selective in-
hibitor (898 or 233). Nascent DNA was labeled with
BrdU prior to harvesting. Changes in BrdU incorpor-
ation were assessed by slot blot analysis using equal
amounts of genomic DNA isolated from DMSO-, 898-
or 233-treated cells. We observed a two-fold reduction
in BrdU incorporation in cells treated with the 898 or
233 when compared to the untreated control cells
(Figure 2B and Additional file 9: Figure S9). Import-
antly, this finding suggests that Hdacs1,2 activities are
required for efficient synthesis of nascent DNA during
DNA replication.
Abrogating histone deacetylase 1 and 2 functions affects
replication fork velocity and activates the replication
stress response
Defective DNA replication in the absence of Hdacs1,2 ac-
tivities might be a cause for the reduced BrdU incorpor-
ation in 898- or 233-treated S-phase cells (Figure 2B and
Additional file 9: Figure S9). To test this possibility, we
used the molecular combing assay to examine if loss or in-
hibition of Hdacs1,2 affects replication fork progression.
In the combing assay, cells are sequentially pulse-labeled
with two different halogenated thymidine analogs (IdU,
iodo-deoxyuridine and CldU, choloro-deoxyuridine) to
Figure 2 Inhibition of histone deacetylase 1 and 2 activities within S-phase or their knockdown reduces replication fork velocity.
A. Serum-starved NIH3T3 cells were released into S-phase in the presence of DMSO or 3 μM 898. Fluorescence-activated cell sorting analysis
following bromodeoxyuridine (BrdU)-propidium iodide labeling and staining was performed at 0 h, 12 h, 18 h and 24 h following release into
S-phase. B. Slot blot analysis was performed using the indicated amount of BrdU-labeled genomic DNA from DMSO or 3 μM 898 treated cells.
BrdU incorporation was quantitated using densitometry. C. Fork velocity was measured by DNA combing. After 20 h following release into
S-phase in the presence of DMSO or 3 μM 898, NIH3T3 cells were labeled with IdU (green) for 15 min and then with CldU (red) in the presence
of 250 μM hydroxyurea for 20 min. DNA fibers were prepared and analyzed as described (Methods section). Box plots show average fork velocity
of DNA fibers prepared from four independent 898 or 233 treatments. At least 100 fibers in different areas of the slide from three different slides
were analyzed per experiment. D. Fork velocity was measured in NIH3T3 cells transfected with non-targeting (NT) or Hdacs1,2 (H12) siRNA. Box
plots show average fork velocity from two independent experiments. The ‘box’ in each box plot (C-D) extends from the first to third quartile of
the data, heavy dark line inside the box represents the median, and the ‘whiskers’ extend to data points no more than 1.5 times the interquartile
range from the ends of the box. Open circles represent data points further from the ends of the box than 1.5 times the interquartile range. Two
sided P values were determined using Welch’s two-sample t-test. R statistical computing software (version 2.15.0) was used to construct box plots
and for t-tests.
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subsequent progression of the fork at replicating origins.
After spreading the DNA fibers on a slide (combing),
newly replicated regions are detected using fluorescent
dye-labeled antibodies that specifically recognize the
two different incorporated thymidine analogs. Length
of the fluorescence signal and the labeling time are then
used to calculate the replication fork velocity (Kb/min). In
this assay, defects in replication fork progression or elong-
ation can be further exacerbated via stalling the fork using
a dose of hydroxyurea (HU, a ribonucleotide reductase in-
hibitor) that does not cause fork collapse [24].To measure changes, if any, in the replication fork vel-
ocity upon abrogation of Hdacs1,2 activities, we released
serum-starved cells into S-phase and treated them with
DMSO (vehicle) or with the Hdacs1,2-selective inhibitor
(898 or 233) followed by pulse labeling of nascent DNA
with IdU (Figure 2C). After removing any free IdU, we
performed the second pulse labeling with CldU in the pres-
ence of HU. We then measured the length of the two
pulse-labels to obtain replication fork velocities, which
were further classified into categories based on the distance
travelled by the fork. We performed box plot analysis to
measure the average fork velocity (Figure 2C, 2D). We also
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ine if loss of Hdacs1,2 activities affects fibers of a particu-
lar velocity range (Additional file 10: Figure S10A). With
IdU labeling, replication fork velocities were reduced in
the presence of Hdacs1,2-selective inhibitor (898 or 233)
compared to the control (Figure 2C and Additional file 10:
Figure S10A, see 0.95 to 1.6 Kb/min). Defects in replica-
tion fork progression due to inhibition of Hdacs1,2 were
also evident for CldU labeling in the presence of hydroxy-
urea (HU), which slows/stalls fork progression (Figure 2C
and Additional file 10: Figure S10A). In addition, we ob-
served a severe reduction in the fork velocity upon treat-
ment of NIH3T3 cells with SAHA that inhibits Hdacs1, 2
and 3 (Additional file 11: Figure S11). We further mea-
sured the replication fork velocities in NIH3T3 cells fol-
lowing knockdown of Hdacs1,2. Loss of Hdacs1,2 caused
a decrease in fork velocity (Figure 2D, IdU label and
Additional file 10: Figure S10B), which was further affected
in the presence of hydroxyurea (Figure 2D, CldU label).
This decrease in fork velocities found upon loss of Hdacs1,2
correlates well with that observed upon preventing their
activities using selective inhibitors (Figure 2C). Collectively,
our findings demonstrate that Hdac1,2 functions are re-
quired for maintaining normal replication fork rates.
If stalled forks are not restarted in a timely fashion, it
could result in fork collapse, formation of double strand
breaks and activation of the DNA damage response,
which involves recruitment of ATM and ATR (damage-
activated sensor kinases) to break sites and activation of
the intra-S-phase checkpoint [25,26]. To examine if in-
hibition of Hdacs1,2 activities triggers a DNA damage
response, we performed immunofluorescence analysis
to detect γH2AX (phosphorylated form of H2AX and a
marker of DNA damage [25]) following treatment of
cells with 898 or 233. We observed an increased num-
ber of γH2AX foci, and brighter foci, in 898- or 233-
treated cells compared to the untreated control cells
(Figure 3A, Additional file 12: Figure S12). In addition
to replication stress-induced breaks, loss of Hdacs1,2
also impairs double-strand DNA break repair [27]. The
observed DNA damage response following inhibition of
Hdacs1,2 activities could be due to a cumulative effect
of continuous replication stress response and also fail-
ure to repair breaks induced during S-phase. Knock-
down of Hdacs1,2 also caused an increase in γH2AX
foci in NIH3T3 cells at 72 h post-siRNA transfection
(Additional file 13: Figure S13). In addition, treatment
of wild-type primary mouse embryo fibroblasts with ei-
ther 898 or 233 led to an increase in the percentage of
cells with big and bright γH2AX foci (Additional file 14:
Figure S14). Hence, loss of Hdacs1,2 activates DNA dam-
age response in different cell types. During replication, the
RecA homolog Rad51 foci formation is triggered when forks
get inactivated and collapse under conditions of intensereplication stress [28]. To examine if loss of Hdacs1,2 leads
to collapsed forks, we performed immunofluorescence to
detect Rad51 in S-phase cells in the presence of 898 or 233.
To intensify the replication stress, we used hydroxyurea in
addition to the Hdacs1,2-selective inhibitors. Under these
treatment conditions, a significant increase in the percent-
age of cells with Rad51 foci was observed (Figure 3B and
Additional file 15: Figure S15). Replication protein A (RPA)
is a single-strand DNA binding, trimeric protein complex
comprised of 14, 32 and 70 kDa subunits [29]. RPA has a
well-characterized role in DNA replication, and RPA32 is
phosphorylated by ATM/ATR kinases in response to repli-
cation stress, such as, hydroxyurea treatment [29]. We
found the chromatin-associated levels of phospho-RPA32
induced by hydroxyurea treatment are further increased
upon inhibition of Hdac1,2 activities with 898 or 233 treat-
ment (Figure 3C). This finding correlates well with the
reduced replication fork velocities observed upon abrogat-
ing Hdacs1,2 activities in the presence of hydroxyurea
(Figure 2C, 2D). Moreover, it suggests that abolishing
Hdacs1,2 activities adversely affects replication fork move-
ment and causes replication stress. In addition, we found
increased level of chromatin-associated p53 upon hydroxy-
urea treatment in cells treated with 898 or 233 compared
to the DMSO-treated control cells (Figure 3D), further
confirming the activation of DNA damage response in cells
lacking Hdacs1,2 functions. We used HeLa cells to look at
phoshorylated-RPA32 and p53 levels, as antibodies that
recognize these antigens failed to work in mouse NIH3T3
cells. Collectively, reduced replication fork velocity and ac-
tivation of replication stress response were observed upon
inhibition or loss of Hdacs1,2, which confirm that these
two enzymes are crucial for the efficient progression of the
replication fork.
Inhibiting histone deacetylase 1 and 2 increases histone
acetylation on S-phase chromatin without drastically
altering S-phase gene transcription
We next sought to explore the molecular mechanism(s) by
which Hdacs1,2 might promote replication fork progres-
sion. Reduced fork velocity might be due to a shortage of
cellular dNTP pool, as seen upon hydroxyurea treatment
[30], or alternatively, due to a decrease in transcription of
genes involved in nucleotide biosynthesis. Treatment of
cells with trichostatin A (TSA), a pan-HDAC inhibitor, re-
duced fork velocity, due to its effect on pyrimidine biosyn-
thesis. TSA treatment decreased the expression of CTP
synthetase 1 and thymidylate synthetase genes, which in
turn reduced pyrimidine biosynthesis [31]. To examine
whether reduced fork velocity in 898-treated cells is linked
to defects in transcription, we used RNA-seq to determine
differential gene expression in three independent DMSO or
898-treated S-phase cells. We observed differential expres-
sion of 70 genes, including upregulation of cytochrome
Figure 3 Abolishing histone deacetylase 1 and 2 (Hdacs1,2) activities causes DNA damage and replication stress, but transcription of genes
for replication factors is not affected. A. NIH3T3 cells were treated with either DMSO or 3 μM 898 or 233 for 48 h and immunofluorescence with
anti-γH2AX antibody was performed to examine activation of DNA damage response. B. Immunofluorescence using anti-Rad51 antibody was
performed on serum-starved NIH3T3 cells following a 20 h release into S-phase and treatment with DMSO or 3 μM 898 or 3 μM 233 in the presence of
500 μM HU. A representative image from multiple treatments is shown. C-D. HeLa cells were treated with 3 μM 898 or 233 in the presence of 500 μM
hydroxyurea for 48 h prior to chromatin preparation. Western analysis of chromatin was done to determine changes in RPA32, modified form of RPA32
(RPA32 S4/S8 phosphorylation, p-RPA32) and p53. p, phosphorylated and slow migrating species of RPA32. H3 and TBP (TATA binding protein) serve as
loading controls. E. Total RNA was isolated from NIH3T3 cells released into S-phase following serum starvation and treated for 20 h with either DMSO
or 3 μM 898. RNA samples obtained from three independent DMSO- or 898-treated cells were subjected to sequencing using the Illumina Hiseq2000
sequencer. Relative reads for CTP synthetase (CTPS) and Cyb561 genes in control and treated samples are shown. F. Chromatin was prepared from non-
targeting (NT) or Hdacs1,2 (H12) siRNA transfected cells at 72 h time point for western analyses. H3 and H4 serve as loading controls. G. Serum-starved
NIH3T3 cells were released into S-phase in the presence of DMSO or 3 μM 898. Chromatin extracts were prepared at 0 h (SS, serum-starved), 12 h, 18 h
and 24 h following release for western analyses.
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Additional file 17: Table S1). However, transcript levels for
CTP synthetase 1 gene were not affected in all three inde-
pendently treated samples (Figure 3E). Also, expression of
genes coding for factors involved in DNA replication or
DNA damage response remained unchanged (Additional
file 16: Figure S16B). Therefore, our gene-expression ana-
lysis suggests that the reduced fork velocity and DNA dam-
age observed upon inhibition of Hdac1,2 activities are not
likely due to altered gene transcription.
It is conceivable that Hdacs1,2 might target a non-
histone protein(s) with an important role in DNA replica-
tion. Smc3, a subunit of the cohesin complex, regulates
replication and is acetylated by Eco1 acetyl transferase
[32]. To test whether loss or inhibition of Hdacs1,2 affects
Smc3 acetylation, we used an antibody that specifically
recognizes the acetylated form of Smc3. While Smc3ac
levels on chromatin increased in S-phase cells, we did not
observe any change in the levels of Smc3 or its acetylated
form following treatment with 898 (Additional file 18:
Figure S17A) or following siRNA-mediated knockdown
of Hdacs1,2 (Additional file 18: Figure S17B). These re-
sults suggest that Hdacs1,2 are not involved in regulating
Smc3 or its acetylation, and this agrees well with the re-
cent finding that Hdac8 is involved in Smc3 deacetylation
[33]. It is possible that Hdacs1,2 target some other non-
histone protein(s) involved in DNA replication.
Heterochromatin protein 1 (HP1) has been linked to
assembly and maintenance of heterochromatin and to
DNA replication [34]. HP1 binds methylated H3K9 [35].
Since H3K9,K14ac is increased in the absence of
Hdacs1,2 functions (Figure 1C, Additional file 3:
Figure S3B), we tested whether Hdacs1,2 play a role in
the chromatin binding of replication-associated forms of
HP1 (that is, HP1α and HP1γ) [36] indirectly via their
regulation of histone modifications. We found chromatin-
bound levels of HP1α and HP1γ in 898-treated S-phase
cells were not affected compared to the untreated control
cells (Figure 3F). Similar results were obtained following
knockdown of Hdacs1,2 (Figure 3G). These findings
suggest that global heterochromatin is not affected upon
transient inhibition of Hdacs1,2 activities, and rule out
reduced HP1 binding to chromatin as a reason for
the DNA replication defects observed upon abrogating
Hdacs1,2 functions.
Hdacs1,2 interact with PCNA (Figure 1A) and Hdac1
deacetylates PCNA [37]. Hence, we tested if loss of
Hdacs1,2 affects the chromatin association of PCNA due
to its increased acetylation in S-phase. Western analysis of
chromatin isolated from S-phase cells showed no defects in
the recruitment of PCNA onto chromatin following treat-
ment with 898 (Figure 3G). Given that PCNA moves with
the fork [38], we performed immunofluorescence analysis
to examine if the punctate pattern of PCNA foci, indicativeof replication factories, is still seen in the absence of Hdac1,2
activities. We observed no defects in PCNA foci formation
at both 18 h and 24 h following release from serum starva-
tion in 898-treated S-phase cells (Figure 4A). Therefore, re-
duced fork velocity in the absence of Hdacs1,2 functions is
not due to any change in PCNA loading onto chromatin
during replication.
We then hypothesized that the stalling of the replication
fork in the absence of Hdacs1,2 might be due to changes
in the chromatin template, probably as a result of altered
histone modifications. To test this possibility, we evaluated
whether histone acetylation is increased on chromatin
upon loss of Hdacs1,2 functions. As mentioned above,
newly synthesized histone H4 is acetylated on K5 and K12
residues. Following their deposition onto nascent chroma-
tin these histone marks are deacetylated, as part of the
chromatin maturation process during replication. Chro-
matin maintenance during replication occurs by the con-
certed action of histone chaperones, which carry and
deposit histones onto nascent DNA, and HDACs that
remove these acetylation marks following their depos-
ition [18]. Double immunofluorescence analysis showed
a robust global increase in H4K5ac in cells with punc-
tate PCNA foci following either 898 or 233 treatment
(Figure 4B, 4C). This result suggests that Hdacs1,2
deacetylate H4K5 in S-phase cells. We further examined
the levels of the histone deposition marks (H4K5ac and
H4K12ac) and other histone acetylation marks on chro-
matin in S-phase cells following treatment with DMSO or
898. Indeed, H4K5ac, H4K12ac and H3K9,K14ac were all
increased on chromatin in S-phase cells upon inhibition
of Hdacs1,2 activities (Figure 5A, 5B). In addition to an in-
crease in the acetylation at specific histone H3 or H4 resi-
dues, we found a general increase in the acetylation of
all histones (H3, H4 and H2A or H2B) on chromatin in
S-phase cells using an antibody that recognizes pan-
acetyl lysine following inhibition of Hdacs1,2 activities
(Figure 5A, Additional file 19: Figure S18). Addition of
an acetyl group onto lysine residue neutralizes the posi-
tive charge. Therefore, histone acetylation can alter chro-
matin structure and packaging by affecting histone-DNA
and histone-histone interactions. For instance, H4K16ac
regulates the higher-order chromatin packaging, and
knockdown of Hdacs1,2 increases H4K16ac in U2OS
cells [27,39]. Hence, we tested whether H4K16ac levels in-
creased upon inhibition of Hdacs1,2 activities. Indeed,
chromatin-associated H4K16ac increased upon knock-
down or inhibition of Hdacs1,2 in NIH3T3 cells (Figure 5C,
5D, 5E). Taken together, our findings show that Hdacs1,2
are required for maintaining histone acetylation levels on
chromatin during S-phase. Furthermore, these results put
forth a hypothesis that the stalling of replication forks in
the absence of Hdacs1,2 activities might be due to an al-
tered structure of the chromatin template.
Figure 4 Inhibition of histone deacetylase 1 and 2 (Hdac1,2) activities does not affect proliferating cell nuclear antigen (PCNA)
localization but leads to increased H4K5ac in S-phase cells. A. Serum-starved NIH3T3 cells were released into S-phase in the presence of
DMSO or 3 μM 898 for 18 h or 24 h prior to staining of PCNA for immunofluorescence analysis. Punctate pattern of PCNA staining (arrows)
indicative of replicating cells was seen in both DMSO and 898-treated cells. B. Serum-starved NIH3T3 cells were released into S-phase in the
presence of DMSO or 3 μM 898 (B) or 233 (C) for 24 h and double immunofluorescence was performed using antibodies to stain PCNA and
H4K5ac. Punctate pattern of PCNA staining was used to track cells in S-phase.
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with nascent DNA
In addition to histone modifications, nascent chroma-
tin structure can also be modulated by the action of
ATP-dependent chromatin remodeling enzymes. In-
deed, chromatin-remodeling enzymes are recruited to
replication sites, and are important for repositioning
nucleosomes during DNA replication [40,41]. One such
chromatin remodeler, ISWI/SNF2H/SMARCA5, is tar-
geted to heterochromatic replication foci as part of the
WICH chromatin-remodeling complex [42]. Additionally,
SMARCA5 interacts with Hdac2, and a SMARCA5-Hdac1,2 complex has been proposed to play a role in the
initiation of DNA replication at origins [43]. Therefore, we
hypothesized that loss or inhibition of Hdacs1,2 might
affect SMARCA5 recruitment and/or activity at the repli-
cation forks, which in turn might adversely affect nascent
chromatin structure and replication fork progression.
SMARCA5 levels on chromatin increased in S-phase cells,
but no dramatic changes were observed following inhib-
ition of Hdacs1,2 activities using 898 (Figure 6A). Simi-
larly, chromatin-bound SMARCA5 levels were not
affected upon knockdown of Hdacs1,2 (Figure 6B). To fur-
ther demonstrate SMARCA5 association with replicating
Figure 5 Loss of histone deacetylase 1 and 2 (Hdacs1,2) function increases chromatin-associated histone acetylation. A. Serum-starved
(SS) NIH3T3 cells were released into S-phase in the presence of DMSO or 3 μM 898. Chromatin extracts were prepared at 0 h (SS), 12 h, 18 h, and
24 h following release into S-phase for western analyses to look at changes in histone acetylation. A representative blot from three independent
experiments is shown. Pan-acK, anti-pan-acetyllysine antibody. B. Quantitation for histone acetylation shown in panel A. Average intensity for a
histone acetylation normalized to the total histone level were calculated from three independent experiments. C-D. Western analysis of H4K16ac
using chromatin extracts prepared from NIH3T3 cells treated with DMSO or 898 (C) or 233 (D) for 24 h. E. Western analysis of H4K16ac using
chromatin extracts prepared from non-targeting or Hdacs1,2-siRNA transfected cells. H4 levels serve as loading control. For panels C-E, quantitation for
H4K16ac levels normalized to total H4 level from three independent experiments is shown.
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tect BrdU-labeled nascent DNA following immunopre-
cipitation. Cells were pulse-labeled with BrdU prior to
formaldehyde crosslinking. Following chromatin immu-
noprecipitation with anti-SMARCA5 antibody, nascent
DNA was detected using an anti-BrdU antibody in slot
blot analysis. To confirm the validity of this modified
ChIP assay, we performed BrdU-pulse chase analysis to
look at the kinetics of PCNA loading onto nascent
DNA in HeLa cells. In agreement with previously pub-
lished results [13], PCNA loading to nascent DNA oc-
curred rapidly within 15 min and disappeared after a
30-min chase (Figure 6C). In mouse NIH3T3 cells, we
failed to obtain significant enrichment for the chromatin-
bound PCNA relative to the background signal using the
same antibody (data not shown). We examined the kinet-
ics of SMARCA5 loading in these pulse-chase experi-
ments in both HeLa and NIH3T3 cells. Our results
showed that BrdU-labeled nascent DNA was present in
the immunoprecipitate obtained using anti-SMARCA5
antibody at all chase time-points in both NIH3T3 and
HeLa cells (Figure 6D-E). Additionally, inhibition or loss
of Hdacs1,2 did not affect SMARCA5 association with
nascent DNA (Figure 6F-G). It is conceivable that these
bulk chromatin analyses might not allow detection of localchanges at the replication forks. Therefore, we tested
SMARCA5 occupancy at candidate replicating loci using
ChIP assays. We found an increase in SMARCA5 occu-
pancy at candidate early, mid- and late-replicating loci in
S-phase cells when compared to its occupancy at these
loci in the G0/G1 phase (Figure 7). We did not observe
any significant change in SMARCA5 occupancy at these
loci following treatment with Hdacs1,2-selective inhibitor
(Figure 7). Taken together, these results demonstrate that
SMARCA5 associates with sites of replication and its
binding to nascent DNA and/or S-phase chromatin is not
dependent on Hdacs1,2 activities.
Loss of histone deacetylase 1 and 2 activities increases
H4K16ac on nascent DNA and alters nascent chromatin
structure
ISWI-family chromatin remodelers have a C-terminal
SANT domain that binds histones and the histone
H4 N-terminus is required to stimulate ISWI ATPase
activity [44]. H4K16ac inhibits the ISWI-family chroma-
tin remodeling ATPases [15]. Therefore, H4K16ac can
inhibit chromatin remodeling in addition to its role in
preventing chromatin compaction. Since H4K16ac is in-
creased upon loss or inhibition of Hdacs1,2 (Figure 5C-E),
we hypothesized that increased H4K16ac at replication
Figure 6 SMARCA5 associates with nascent DNA. A. Serum-starved NIH3T3 cells were released into S-phase in the presence of DMSO or 3 μM
898. Chromatin extracts were prepared at 0, 12 h, 18 h, and 24 h following release into S-phase for western analyses to look at SMARCA5 levels.
B. Chromatin was prepared from either non-targeting (NT) siRNA or Hdac1,2 (H12) siRNA transfected cells at 72 h time-point to look at SMARCA5
levels. TATA binding protein (TBP) serves as a loading control. C. HeLa cells were labeled with bromodeoxyuridine (BrdU) for 30 min. Cells
were then washed to remove unincorporated BrdU and cultured in media without BrdU for indicated periods of time (chase). Chromatin
immunoprecipitation (ChIP) was performed with anti-proliferating cell nuclear antigen (PCNA) antibody. BrdU labeled DNA present in input DNA
and those associated with PCNA were assessed in slot blot analysis using an anti-BrdU antibody. D-E. BrdU-pulse chase coupled to slot blot
analysis in HeLa (D) or NIH3T3 (E) cells to determine the kinetics of SMARCA5 association to nascent DNA at the indicated chase time points.
F-G. NIH3T3 cells were treated with either DMSO or 898 for 24 h or transfected with non-targeting or Hdac1,2 siRNA and labeled with 20 μM
BrdU for 1 h before harvesting. ChIP of SMARCA5 or rabbit IgG control was done and increasing volumes of ChIP DNA were spotted onto a
membrane using slot blot and probed with anti-BrdU antibody. In F-G, a representative blot from three independent experiments is shown. UT
refers to untreated.
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SMARCA5 activity and/or by affecting nascent chromatin
compaction/packaging. Given our bulk chromatin analysis
(Figure 5C-E), we first tested whether H4K16ac was present
on nascent DNA. Indeed, using the modified ChIP assay,
we found H4K16ac associates with BrdU-labeled nascent
DNA in both HeLa and NIH3T3 cells (Figure 8A-B).
Additionally, inhibition or loss of Hdacs1,2 increased
H4K16ac levels associated with newly synthesized DNA
(Figure 8C, Additional file 20: Figure S19). Standard
ChIP analysis showed the presence of H4K16ac at can-
didate replication origins (Figure 8D-F). Interestingly,
H4K16ac levels at these loci are higher in G0/G1 phase
and are reduced once cells enter and progress through
the S-phase, likely due to deacetylation by HDACs. In-
deed, H4K16ac levels are increased at these origins fol-
lowing treatment with Hdacs1,2-inhibitor in S-phase
cells (Figure 8D-F). Taken together, these results show that
H4K16ac occurs at sites of replication and emphasizes adirect role for Hdacs1,2 in the deacetylation of this mark
during replication in mammalian cells. Furthermore, it
puts forth the possibility that increased H4K16ac at repli-
cation forks might inhibit SMARCA5 activity and/or chro-
matin packaging, which in turn might adversely affect
nascent chromatin structure and replication fork rates.
Given the increase in H4K16ac on nascent chromatin,
we sought to determine whether Hdacs1,2 play a role in
maintaining chromatin structure during replication.
Therefore, we tested the sensitivity of nascent DNA to
micrococcal nuclease (MNase) digestion in the absence
of Hdacs1,2 functions. Cells were treated with either
DMSO (control) or 898 to inhibit Hdacs1,2 (Figure 9A),
or transfected with non-targeting siRNA (control) or
Hdacs1,2-specific siRNA to knockdown the two enzymes
(Figure 9B). Newly synthesized DNA was pulse-labeled
with BrdU prior to nuclei isolation and MNase digestion.
BrdU-labeled nascent DNA was detected using an anti-
BrdU antibody. No defects in the global chromatin
Figure 7 SMARCA5 associates with candidate replication
origins during S-phase. Serum-starved (SS, 0 h) NIH3T3 cells were
released into S-phase in the presence of DMSO or 3 μM 898. SMARCA5
occupancy at α-globin (early replicating origin), pancreatic amylase
(mid-late replicating) and β-globin (late replicating) in synchronous
NIH3T3 cells were determined using chromatin immunoprecipitation
(ChIP) assays. Average fold enrichment for SMARCA5 relative to input
from two independent experiments is shown.
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Hdacs1,2 functions, as evidenced by the ethidium bromide
staining of MNase-digested DNA (Figure 9A-B, left
panels). For BrdU-labeled nascent DNA, we observed a
consistent increase in dinucleosomes and trinucleosomes
released at lower MNase concentrations followingtreatment with 898 compared to DMSO alone (Figure 9A,
compare lanes 6 and 7 to 2 and 3). Similar results were
obtained following knockdown of Hdacs1,2 when com-
pared to the control (Figure 9B, compare lanes 6 and 7 to
2 and 3). At high MNase concentration, nascent DNA as-
sociated with mononucleosomes appears to be very sensi-
tive to nuclease digestion in the absence of Hdacs1,2
functions compared to the control (Figure 9A-B, compare
lanes 4 and 8). This apparent increased sensitivity of nas-
cent mononucleosomal DNA might be due to reduced
BrdU incorporation in the absence of Hdacs1,2 functions
(Figure 2B). Alternatively, the structure of nascent DNA
associated mononucleosomes might indeed be altered in
the absence of Hdacs1,2 activities due to increased histone
acetylation, and thus, rendering them more sensitive to
MNase digestion. To test this possibility, we digested nu-
clei isolated from S-phase cells treated with DMSO or 898
extensively with MNase and purified the DNA associated
with mononucleosomes (approximately 146 bp). This
purified DNA was then used as the template in quantita-
tive PCR to assess sensitivity of nucleosomes at candidate
replicating loci to nuclease digestion. We found nucleo-
somes at α-globin and β-globin loci to be sensitive to
nuclease digestion following treatment with 898 to in-
hibit Hdacs1,2 activities (Figure 9C). We were unable to
amplify across the pancreatic amylase locus following
MNase digestion, probably because this region might be
nucleosome-deficient or contains labile nucleosomes
that are hypersensitive to nuclease digestion. Collect-
ively, our MNase digestion assays show that Hdacs1,2
activities are required to maintain normal structure of
nascent chromatin during DNA replication.
Loss of ISWI-family chromatin remodeler SMARCA5
inhibits replication fork velocity
We next sought to determine whether SMARCA5 plays
a role in the proper progression of DNA replication in
mammalian cells. To this end, we measured replication
fork velocity following knockdown of SMARCA5. We
could achieve efficient knockdown of SMARCA5 in
HeLa cells (Figure 10A), and no significant cell death
was observed at 72 h post-transfection. As described for
Hdacs1,2 (Figure 2C-D), we performed molecular comb-
ing analysis to determine changes in the replication fork
rate following knockdown of SMARCA5 in the absence
or presence of hydroxyurea. We found a consistent re-
duction in the replication fork velocity in the absence of
SMARCA5 (Figure 10A, IdU label, Additional file 21:
Figure S20, see high velocity 0.63 to 1.6 Kb/min rates),
which was further exaggerated in the presence of hy-
droxyurea (Figure 10A, CldU label, Additional file 21:
Figure S20, see 0.32 to 1.6 Kb/min rates). Taken together,
our results show that SMARCA5 is required for main-
taining normal replication fork rates similar to Hdacs1,2.
Figure 8 Loss of histone deacetylase 1 and 2 (Hdacs1,2) increases H4K16ac on nascent DNA and at replication origins. A-B.
Bromodeoxyuridine (BrdU) pulse chase was performed to determine association of H4K16ac with nascent DNA at the indicated time points.
C. BrdU-labeled nascent DNA associated with H4K16ac was measured by slot blot using input or immunoprecipitated DNA from cells transfected
with non-targeting siRNA (NTsi) or Hdacs1,2-specific siRNA (H12si). BrdU-labeled nascent DNA was detected using an anti-BrdU antibody. Average
BrdU signal of high and medium volume of chromatin immunoprecipitation (ChIP) DNA spotted on the slot was quantified by the Image J
software and is shown on the right hand side of the panel. D-F. Changes in H4K16ac levels at candidate origins were measured by ChIP assays
using NIH3T3 cells either serum-starved (SS, 0 h) or released into S-phase for the indicated time periods in the presence of either DMSO or
3.75 μM 898. Fold enrichment for H4K16ac was determined after normalization of H4K16ac occupancy to the occupancy of H4 at a given locus
from three independent treatments.
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vated in the absence of SMARCA5. Loss of SMARCA5
alone caused a very modest increase in the percentage of
cells with γH2AX foci in HeLa cells (approximately 10%)
(Additional file 22: Figure S21). However, loss of
SMARCA5 combined with hydroxyurea treatment led to
an increase in the percentage of cells with bright γH2AX
staining (Additional file 22: Figure S21). These results to-
gether suggest that SMARCA5 is required for the proper
progression of DNA replication and maintaining genome
stability during S-phase similar to Hdacs1,2.
Discussion
Histone deacetylase 1 and 2 control nascent chromatin
structure
Modulation of chromatin structure around a replication
fork is achieved by the concerted action of histone variants,histone modifying enzymes, chromatin remodelers, his-
tone chaperones and numerous chromatin-binding fac-
tors. It is conceivable that histone acetylation might be
required to maintain a permissive chromatin conform-
ation for the replication fork to progress. During S-phase,
newly synthesized histone H4 is acetylated at K5 and K12
residues and deposited onto nascent chromatin by CAF-1,
a histone chaperone [18]. Also, H4K16ac is enriched at
initiation zones and at early replication regions [45]. Re-
moval of H4K5ac and H4K12ac by HDACs following their
deposition onto nascent chromatin was proposed to be an
event in chromatin maturation during DNA replication
[18]. Using selective inhibitors, we now show that
Hdacs1,2 target histone deposition marks within S-phase
cells and on nascent DNA (Figure 5A). Since H4K16ac
prevents chromatin compaction, we propose a model,
wherein Hdacs1,2 remove H4K16ac to allow chromatin
Figure 9 Loss of histone deacetylase 1 and 2 (Hdacs1,2) affects nascent chromatin structure. A-B. Nuclei were isolated from cells treated
with either DMSO or 898 (A), or from cells transfected with non-targeting (NT) siRNA or Hdacs1,2-siRNA (B), bromodeoxyuridine (BrdU)-labeled
nuclei were digested performed with various micrococcal nuclease (MNase) concentrations (0, 0.5, 2 and 8 units) for 5 min at 37°C. Equal amount
of purified DNA was subjected to agarose gel electrophoresis. Pixel intensity of mono, di- and trinucleosomes obtained from 0.5 units MNase for
control and knockdown samples and 2 units MNase for DMSO or inhibitor-treated samples were measured using the ImageJ software.
Quantitative data for nucleosome levels and input levels were obtained using densitometry from four independent experiments for inhibitor
treated samples and two independent experiments for knockdown samples. Nucleosome intensities were normalized to input intensities. The
average intensity for control was set as 1 and fold-increase in nucleosome intensities in treated samples were determined in comparison to the
control. Error bars denote standard error of the mean from multiple experiments. NTsi and H12si refer to non-targeting and Hdacs1,2-siRNA,
respectively. C. Mononucleosome sensitivity was determined in S-phase synchronized cells as described in the Methods section. Fold-change in
MNase sensitivity for a given region in S-phase cells was determined by qRT-PCR and normalized to the sensitivity of the locus in serum-starved
samples. The plotted data represents an average +/− standard error of 3 independent treatments and the experiment was repeated two times.
D, 8 and 2 refer to DMSO, 898 and 233 treatments, respectively. EtBr, ethidium bromide.
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(Figure 10B). Indeed, we find that in the absence of
Hdacs1,2 activities the nascent chromatin and nucleo-
somes at candidate replication loci are more susceptible to
nuclease digestion (Figure 9), indicative of a more ‘permis-
sive’ or ‘loose’ chromatin conformation. Hence, it is tempt-
ing to speculate that this atypical chromatin structure
signals the replication machinery to stall, collapse, and
trigger the DNA damage response. The resulting double-
strand break and S-phase lesions could cause severe
chromosome segregation defects. We find DNA damage
and stress response activation upon inhibiting Hdacs1,2
(Figures 3A-B, Additional files 12, 13, 14: Figures S12,S13, S14), which corroborates previous findings that
loss of Hdacs1,2 causes severe mitotic catastrophe [8].
Role for histone deacetylase 1 and 2 in DNA replication via
regulation of SMARCA5 function
Chromatin maturation not only involves histone deacetyla-
tion, but also nucleosome remodeling. Human cells con-
tain two isoforms of ISWI: SNF2H and SNF2L [46]. The
SNF2H/SMARCA5 complex remodels nucleosomes to
allow smooth movement of the fork, especially through
the heterochromatin [47]. SMARCA5 interacts with
PCNA and with Hdacs1,2 [43,48]. In yeast, loss of Iswi2
and Ino80 causes defects in replication fork progression
Figure 10 Knockdown of SMARCA5 decreases replication fork velocity. A. Western analysis of whole cell extract prepared from HeLa cells
transfected with either non-targeting (NT) siRNA or SMARCA5 siRNA at 72 h time point following transfection. Histone deacetylase 1 (Hdac1) and
β-actin serve as loading controls. Replication fork velocity was measured in HeLa cells transfected with either non-targeting (NT) or SMARCA5
siRNA at 72 hr time point following transfection. Box plots from were derived from data obtained in three independent experiments.
Representative DNA fibers are shown in the left panel. B. Model for the functions of Hdacs1,2 during DNA replication. Hdacs1,2 and SMARCA5
interact with proliferating cell nuclear antigen (PCNA) and recruited to forks during replication. Hdacs1,2 deacetylate H4K5ac, H4K12ac and
H4K16ac. H4K12ac and H4K16ac inhibit SMARCA5 nucleosome remodeling activity. Deacetylation restores chromatin structure allowing proper
inter-nucleosomal interactions and remodeler-driven nucleosome positions to support the progression of the replication fork. Green line, newly
replicated DNA. Orange disk, nucleosome with histone tail(s). Blue circle, acetyl group.
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through heterochromatin, and depletion of SMARCA5
decreases BrdU incorporation in HeLa cells [47]. However,
function for SMARCA5 in fork elongation in mammalian
cells was not known. In this study, we show that
SMARCA5 associates with nascent DNA (Figure 6D), and
its occupancy on chromatin and at candidate replication
origins increases in S-phase (Figure 6A and Figure 7). Im-
portantly, we show that SMARCA5 has a direct role in
controlling fork elongation, as its deletion reduces replica-
tion fork rates (Figure 10A).
The ISWI family chromatin remodelers have the cata-
lytic ATPase domain and a SANT domain that binds the
H4 tail. H4K16ac and H4K12ac were shown to interfere
with the ability of ISWI to interact with the H4 tail and
they inhibit the ATPase activity of the ISWI complex
[15,16]. We show Hdacs1,2 target H4K16ac on newly
synthesized DNA (Additional file 20: Figure S19). Also,
we show that H4K12ac and H4K16ac are targeted by
Hdacs1,2 in S-phase cells (Figure 5A, Figure 8D-F).
Interestingly, we find an inverse correlation for theoccupancy of H4K16ac and SMARCA5 at candidate repli-
cation origins (α-globin, β-globin and pancreatic amylase)
in S-phase cells (Figure 7, Figure 8D-F). While H4K16ac
levels are high at these loci in the non-replicating G0/G1
phase, they are reduced by Hdacs1,2 as cells enter and
progress through the S-phase (Figure 8D-F). On the other
hand, SMARCA5 levels are low at these loci in G0/G1
phase and increase during the S-phase. Therefore, these
findings support a model (Figure 10B), wherein Hdacs1,2
might regulate SMARCA5 activity at the replication forks
via removal of H4K12ac and H4K16ac. Increase in
H4K12ac and H4K16ac around the fork upon loss or in-
hibition of Hdacs1,2 functions might inhibit SMARCA5-
mediated chromatin remodeling, which is necessary for
fork progression (Figure 10A), resulting in fork stalling
and collapse. Collectively, we favor a model (Figure 10B),
wherein Hdacs1,2 control nascent chromatin structure in
two modes: one, affecting nucleosome structure and chro-
matin packaging by directly regulating histone acetylation
and two, by regulating nucleosome remodeling via modu-
lation of chromatin remodeler activity. Since abrogation of
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replication and compromise chromatin and genome sta-
bility during S-phase, selective inhibition of Hdacs1,2
might be an efficient therapeutic strategy to minimize
the side effects of pan-HDIs that are currently used in
cancer treatment.
Conclusions
In this study, we report functions for Hdacs1,2 in
maintaining normal replication fork progression and in
nascent chromatin maintenance using novel Hdacs1,2-
selective inhibitors and siRNA-mediated genetic knock-
down systems. SAHA, a pan-inhibitor that targets all
class I HDACs, was shown to affect replication fork vel-
ocity in cancer cells without affecting transcription [50].
Here, we show that Hdacs1,2 (a subset of SAHA targets)
play a direct role in DNA replication without disrupting
transcription of genes involved in DNA replication, re-
pair or nucleotide biosynthesis. We further show that
inhibiting Hdacs1,2 alters nascent chromatin architec-
ture (histone acetylation and compaction), reduces repli-
cation fork velocity and triggers DNA damage response.
These findings highlight the important role for Hdacs1,2
in genome stability maintenance. In addition, we show
that SMARCA5, an ISWI-family chromatin remodeler, is
present on nascent chromatin and is required for proper
progression of DNA replication. Therefore, in this study,
we have connected the functions of a chromatin re-
modeler (SMARCA5), histone modifications (H4K12ac
and H4K16ac) and histone deacetylases (Hdacs1,2 that




HeLa and HEK 293 cells were cultured in DMEM containing
10% fetal bovine serum (Hyclone, Logan, UT, USA), 1%
penicillin-streptomycin and 1% glutamine. NIH3T3 cells
were serum starved for 72 h in 0.5% serum containing
media. NIH3T3 cells were cultured in DMEM (Cellgro™,
Tewksbury, MA, USA) containing 10% fetal calf serum,
1% penicillin-streptomycin and 1% glutamine. NIH3T3
cells were serum starved for 72 h in 0.5% serum
containing media. Fibrosarcoma cells for conditional
knockout of Hdac1,2 or Hdac3 were cultured as de-
scribed previously [8].
siRNA knockdown
Cells were transfected with siGenome SMART pool for
mouse Hdac1, or siGenome SMART pool for mouse
Hdac2, siGenome SMART pool for human SMARCA5,
or with non-specific control pool (siRNA negative con-
trol) as described previously [14]. All siRNAs were pur-
chased from Dharmacon (Lafayette, CO, USA).Replication fork velocity measurement
NIH3T3 cells transfected with non-targeting (NT) or
Hdac1 & Hdac2 siRNAs were labeled with 20 μM IdU
(iodo-deoxyuridine) for 15 min following 72 h post-
transfection. Cells were washed with PBS and labeled
with 100 μM CldU (chloro-deoxyuridine) in the pres-
ence of 250 μM hydroxyurea for 20 min. Cells were
lysed with spreading buffer (0.5% SDS in 200 mM Tris–
HCl, pH 7.4 and 50 mM EDTA) and DNA fibers were
spread on silane-coated slides. Following fixation and
DNA denaturation, immunofluorescence (IF) was per-
formed using anti-IdU and anti-CldU antibodies and
mouse anti-BrdU-conjugated to Alexa 488 and rat anti-
CldU conjugated to Alexa 594 (secondary antibodies).
Fiber images were captured using an Axioscope micro-
scope. The lengths of approximately 100 fiber tracks
were measured using the ImageJ software. The fiber
length (μm) was converted into Kb DNA length after
taking the stretching factor (1 μm = 2 Kb DNA) into
consideration. The resulting value was then divided by
the incubation time to obtain the fork velocity.
Chromatin immunoprecipitation assay
ChIP assays were performed as described previously [51].
Immunofluorescence analysis




BrdU-PI analysis was performed as described previously [14].
PCR primers
PCR primers for ChIP analysis at replication origins were
described previously [17].
Nuclei isolation for micrococcal nuclease digestion
NIH3T3 cells were labeled with 20 μM BrdU, washed
with ice-cold phosphate-buffered saline (PBS). Cell lysis
buffer (10 mM Tris–HCl, pH 7.4, 300 mM sucrose, 3 mM
CaCl2, 2 mM Mg(CH3COO)2, 0.5% NP-40, 5 mM
dithiothreitol (DTT) and 1X Roche protease inhibitor
cocktail) was added to the plate and left on ice for 5 min.
Cells were scraped following lysis, Dounce homogenized
fifty times, spun at 1000 rpm for 5 min at 4°C. Nuclei were
stored in nuclei storage buffer (50 mM Tris- HCl, pH 8.3,
40% glycerol, 0.1 mM EDTA, 5 mM Mg(CH3COO)2,
5 mM DTT and 1X Roche protease inhibitor cocktail)
and stored at −80°C until use.
Immunoprecipitation
Nuclear extract was prepared in RIPA buffer sup-
plemented with protease inhibitors (Roche) and precleared
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USA) for 20 min at 4°C with constant rotation. The
precleared lysate was then incubated with anti-PCNA
antibody for 12 h at 4°C with constant rotation. Protein
A-agarose beads equilibrated in RIPA buffer was then
added to the samples, and pull-down was done at 4°C for
1 h with constant rotation. The beads were then washed
with RIPA buffer for three times and resuspended in 1X
SDS sample buffer before Western analysis.
Nuclear and chromatin extract preparation for
immunoprecipitation and western blot analyses
NIH3T3 cells were washed with ice-cold PBS. Cells were
scraped and spun at 3000 rpm at 4°C for 5 min. The cell
pellet was resuspended in buffer A (10 mM HEPES, pH
7.9, 10 mM KCl, 1.5 mMMgCl2, 0.34 M sucrose, 10% gly-
cerol, 1 mM dithiothreitol (DTT), and protease inhibitor
cocktail). Triton X-100 (0.1% final concentration) was
added to the extract, and incubated on ice for 8 min. Nu-
clei (fraction P1) were collected by centrifugation (5 min,
8000 rpm, 4°C). The nuclear pellet was resuspended in
RIPA buffer containing protease inhibitor cocktail and
sonicated to solubilize the chromatin. To prepare chroma-
tin extract, the isolated nuclei (fraction P1) were re-
suspended in hypotonic buffer (3 mM EDTA, 0.2 mM
EGTA, 1 mM DTT) supplemented with protease inhibitor
cocktail (Roche, Penzberg, Upper Bavaria, Germany) and
incubated on ice for 30 min. Following centrifugation, the
pellet was resuspended in RIPA buffer containing protease
inhibitors and sonicated briefly to solubilize the chroma-
tin. Protein concentrations were measured using Bio-Rad
Protein Assay or Bio-Rad DC™ protein assay kits (Bio-Rad,
Hercules, CA, USA)’.
Histone deacetylase assay
NIH3T3 cells were treated with DMSO (control) or the
selective HDAC inhibitors for 24 h. Nuclei were isolated
as described above and resuspended in HERR buffer (20
mM HEPES pH 7.9, 150 mM KCl, 0.1% NP40, 10% gly-
cerol, 2 mM EDTA). Extracts were sonicated and
precleared with Protein A-agarose beads (Millipore) for
20 min at 4°C with constant rotation. The precleared
lysate was then incubated with anti-Hdac1 or -Hdac2 or -
Hdac3 antibodies for 4 hr at 4°C with constant rotation.
Protein A-agarose beads were then added to samples and
pull down was done at 4°C for 1 hr with constant rotation.
The beads were then washed with HERR buffer for three
times and HDAC assay was performed as per the
recommended protocol provided with the Fluor-de-Lys™
HDAC fluorometric activity assay kit (Enzo Life Sciences,
Farmingdale, NY, USA). The activity was measured using
the 2104 EnVision™ Multilabel Reader (PerkinElmer; exci-
tation at 340 nm and emission at 495 and 520 nm). In
vitro HDAC assays were performed using recombinantHDAC enzymes and the Fluor-de-Lys™ HDAC fluoromet-
ric activity assay kit.
Micrococcal nuclease sensitivity analysis of nascent DNA
Nuclei were isolated from cells treated with DMSO
(control) or Hdacs1,2-selective inhibitor (898), or from
cells transfected with non-targeting siRNA or Hdacs1,2-
specific siRNA followed by labeling with 20 μM BrdU
for 1 hr. MNase digestion of nuclei was performed es-
sentially as described previously [51]. Briefly, equal num-
bers of nuclei were digested with 0, 0.5, 2 or 8 units of
MNase (Worthington Biochemical Co., Lakewood, NJ,
USA) for 5 min at 37°C. Nuclease digestion was termi-
nated following addition of equal volume of 2X stop buffer
(20 mM Tris. Cl, pH 7.5, 200 mM NaCl, 2% SDS and 20
mM EDTA). Following nuclease digestion, genomic DNA
was isolated using the Easy-DNA™ Kit (Invitrogen) as per
the manufacturer’s instructions. DNA concentration was
measured using NanoDrop 1000 spectrophotometer
(ThermoScientific). Undigested DNA (0.5 μg) or MNase-
digested DNA (1 μg) were resolved in a 1.5% agarose gel
and stained with ethidium bromide. The DNA was then
transferred onto a charged membrane (Hybond™-N+, GE
Healthcare, Pittsburgh, PA, USA) using capillary transfer
following the standard Southern blotting procedure. The
membrane was subjected to UV crosslinking to immobilize
DNA. Membrane-bound BrdU-labeled nascent DNA was
detected by Western blotting using an anti-BrdU antibody
(used at 1:2000 dilution).
Locus-specific micrococcal nuclease sensitivity assay
NIH3T3 cells were serum starved for 72 h and released
into serum-rich medium to progress into S-phase in the
presence of DMSO or 3 μM Hdacs1,2-selective inhibitor
(898) and treated for 20 h prior to crosslinking with
0.1% formaldehyde for 10 min. Serum-starved NIH3T3
cells prior to release into S-phase were also crosslinked
similarly with formaldehyde. Crosslinking was quenched
by adding glycine (125 mM final concentration) and in-
cubating for 5 min at room temperature. Nuclei were
isolated as described above and counted. Equal number
of nuclei from different treatments (0.5 × 106) were
washed once in Buffer D (50 mM Tris- HCl, pH 8.0,
25% glycerol, 0.1 mM EDTA, 5 mM Mg(CH3COO)2, 5
mM DTT) and then resuspended in 0.2 ml of Buffer
MN (15 mM Tris, pH 7.4, 60 mM KCl, 15 mM NaCl,
0.5 mM DTT, 0.25 M sucrose and 1 mM CaCl2). Nuclei
(0.1 ml) were digested with micrococcal nuclease
(10 units, Worthington Biochemical Co.) by incubation
for 7 min at 37°C and 400 μg RNase A (Qiagen, Vinlo,
Limberg, Germany) was added and digestion was contin-
ued for an additional 3 min. Digestion was stopped by
adding an equal volume of 2X stop buffer (20 mM Tris.
Cl, pH 7.5, 200 mM NaCl, 2% SDS and 20 mM EDTA).
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DNA control) an equal volume of 2X stop buffer was
added. DNA from undigested and MNase-digested nu-
clei was isolated using Qiagen DNeasy™ Kit. MNase-
digested DNA was resolved in a 1.8% agarose gel.
Mononucleosomal DNA (approximately 146 bp) was
excised and extracted from the gel using Qiagen Gel
Extraction Kit. The yield of undigested DNA and puri-
fied mononucleosomal DNA was measured using
Quant-iT™ PicoGreen™ dsDNA Assay Kit (Invitrogen,
Carlsbad, CA, USA) in a Qubit™ 2.0 Fluorometer. DNA
amounts obtained from various samples were normal-
ized to make them equal. Equal amount of DNA was
then used as template in qPCR in real time using the
primers for α-globin, β-globin and pancreatic amylase
loci. For each primer, percentage protection was calcu-
lated by comparing Ct values of undigested DNA versus
mononucleosomal DNA for DMSO or 898 treatments
and further normalized to Ct values of undigested DNA
versus mononucleosomal DNA obtained from the serum
starved cells.
Slot blot analysis of bromodeoxyuridine-labeled DNA
For measuring BrdU incorporation, NIH3T3 cells in
S-phase were treated with DMSO or 3 μM Hdacs1,2-se-
lective inhibitor (898) for 12 h, 18 h or 24 h followed by la-
beling of cells with 20 μM BrdU for 1 hr. Genomic DNA
was isolated using Qiagen DNeasy™ Kit and extensively
digested with RNaseA. DNA was quantified in a Qubit™
2.0 Fluorometer using Quant-iT™ PicoGreen™ dsDNA
Assay Kit (Invitrogen). Equal amount DNA (500 ng) from
the different samples was resuspended in 40 μl water and
denatured by adding 10 volumes of 0.4 N NaOH and incu-
bation at room temperature for 30 min. Equal volume of 1
M Tris. Cl, pH 6.8 was added to neutralize and samples
were placed on ice. Aliquots were made to obtain varying
amounts of DNA (50, 25 and 12.5 ng) for each sample in a
total volume of 100 μl. DNA was then transferred on to a
Zeta-Probe GT Membrane (Bio-Rad, Hercules, CA, USA)
using a Slot Blot apparatus (Schleicher and Schuell
Minifold II). DNA was immobilized to the membrane
using a UV crosslinker and western blotting was done with
anti-BrdU antibody. The linear range for detecting BrdU-
labeled DNA was initially determined using DNA isolated
from the DMSO control. Using a two-fold serial dilution
of DNA, we determined that 50 ng to 6.25 ng to be in the
linear range of detection in western blotting using the
anti-BrdU antibody (1:500 dilution) and ECL2 Western
Blotting Substrate (Thermo Scientific Pierce, Waltham,
MA, USA).
For the analysis of BrdU-labeled DNA obtained from
ChIP assays, input and ChIP DNA were eluted in 50 μl
water. The input DNA yield was measured using
NanoDrop 1000 spectrophotometer (ThermoScientific)to ensure that the DNA amount to be used in Slot Blot
assay remains in the linear range of detection (<50 ng).
The input and immunoprecipitated DNA (50 μl) were
denatured by adding 2.5 volumes of 0.4 N NaOH and in-
cubating at room temperature for 30 min. Equal volume
of 1 M Tris–HCl, pH 6.8 (175 μl) was then added to
neutralize and samples were placed on ice. A serial dilu-
tion of DNA from input and immunoprecipitated DNA
for the Slot Blot assay were prepared as follows: For input
DNA, 100 μl denatured DNA; 50 μl denatured DNA + 50
μl H2O; 25 μl denatured DNA + 75 μl H2O. For ChIP
DNA, 200 μl denatured DNA; 100 μl denatured DNA +
100 μl H2O; 50 μl denatured DNA + 150 μl H2O. The
DNA were then transferred on to a Zeta-Probe GT Mem-
brane (Bio-Rad, Hercules, CA, USA) using a Slot Blot ap-
paratus (Schleicher and Schuell Minifold II) and processed
as described above. For the modified ChIP assays with
Brdu pulse-chase, NIH3T3 or HeLa cells were labeled
with 20 μM BrdU for 30 min. Following BrdU-labeling,
cells were washed twice with PBS to remove unincorpor-
ated BrdU and grown in fresh medium. For the chase, cells
were fixed with formaldehyde for ChIP analyses at 15 min,
30 min and 60 min time points.
RNA-Seq analysis
Total RNA was isolated from NIH3T3 cells that were re-
leased into S-phase from serum starvation for 20 h either
in the presence of DMSO or 3 μM 898 using the Versagene
RNA isolation kit (5 Prime). RNA was prepared from three
different sets of DMSO- and 898-treated cells and se-
quenced using the Illumina Hiseq2000 sequencer. Standard
gene analysis was performed using the open source USeq/
DESeq analysis packages. In brief, this involves aligning
each replica dataset to a genome index that has the stand-
ard mm10 chromosomes plus an artificial chromosome
containing all known and all theoretical splice junctions.
After alignment splice junction coordinates are converted
to genomic coordinates, counts for each gene was collected,
and a multi-replica treatment versus control comparison
was performed using DESeq (http://genomebiology.com/
2010/11/10/R106). Genes passing two thresholds, an FDR
of <10% and absolute log2 ratio of 1, were considered dif-
ferentially expressed and used in subsequent analysis. A
window scanning, no known annotation analysis was also
performed using the USeq MultipleReplicaScanSeqs appli-
cation. This analysis generated the genome wide log2 ratio
and FDR window summary tracks.
Protein analysis
For preparation of whole cell extracts, cell pellets were
washed with PBS and sonicated in RIPA buffer with prote-
ase inhibitors (Roche protease inhibitor cocktail) prior to
western analyses. Antibodies used in this study are listed
in the supplementary table (Additional file 23: Table S2).
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Ad-Cre infection of fibrosarcoma cells was performed as
described previously [14].Additional files
Additional file 1: Figure S1. Hdac1 and Hdac2 are present at
candidate mid- and late-replication origins during S-phase. A-B. Serum-
starved NIH3T3 cells were released into S-phase and cells were cross-
linked at 12 h, 18 h and 24 h time points following release. Serum
starved cells (0 h) were also cross-linked and used as a control. The levels
of Hdac1 and Hdac2 at pancreatic amylase (mid-late replicating) and
β-globin (late replicating) in synchronized NIH3T3 cells were determined
using ChIP assays. Data represents average of three independent ChIP
experiments. Error bars, standard error of the mean.
Additional file 2: Figure S2. Loss of Hdac1 alone or Hdac2 alone has
no effect on H4K5ac. Fibrosarcoma cells containing floxed alleles of
Hdac1 (Hdac1Fl/Fl) were infected with Ad-Cre (Hdac1Fl/Fl + Cre) to deplete
Hdac1. Cells without Ad-Cre infection (Hdac1Fl/Fl –Cre) were used as wild
type control. Also, cells without Ad-Cre infection were transfected with
Hdac2-specific siRNA (Hdac1Fl/Fl + Hdac2siRNA) to deplete only Hdac2.
Western blot of chromatin fractions was performed to check depletion of
either Hdac1 or Hdac2 and the levels of H4K5ac. H4 was used as the
loading control. KO, knockout; KD, knockdown; WT, wild type.
Additional file 3: Figure S3. Characterization of novel Hdac1,2-selective
inhibitors. A. In vitro enzyme assays using recombinant HDAC proteins to
determine the specificity of 233 and 898 towards Hdacs1 and 2. Numbers in
the table represent IC50 values obtained for an inhibitor-enzyme
combination in the in vitro HDAC assays. AFU refers to arbitrary fluorescent
units. B. Dose range of RGFP898 that induces increase in histone acetylation
was determined by western analysis of whole cell extracts prepared from
NIH3T3 cells following treatment for 24 h with DMSO or increasing
concentrations of 898 (μM). H3 and H4 levels serve as loading controls.
Additional file 4: Figure S4. Western analysis of extracts used in vivo
HDAC enzyme assays. Hdac1 or Hdac2 or Hdac3 were immunoprecipitated
from nuclear extracts following treatment of NIH3T3 cells with either DMSO
(D), 3 μM 898 (panel A) or 3 μM 233 (panel B). Immunoprecipitated HDACs
were then used in enzyme assays to measure inhibition by 898 or 233 (data
shown in Figure 1D-E). Western blots were performed using antibodies
against each HDAC to confirm the presence of the enzyme and the
efficiency of individual immunoprecipitation.
Additional file 5: Figure S5. Effect of 898 and 233 on H4K5ac levels in
cells following conditional knockout of Hdac1,2 or Hdac3. Quantitative
data for western blots shown in Figure 1: H-I. A-B. Fibrosarcoma cells
containing floxed alleles of Hdac1 and Hdac2 (Hdac1Fl/FlHdac2Fl/Fl) were
infected with Ad-Cre for 48 h to deplete both Hdac1 and Hdac2, and
then treated with either DMSO or 3 μM 233 (A) or 3 μM 898 (B) for 24 h.
C-D. Fibrosarcoma cells containing floxed alleles of Hdac3 (Hdac3Fl/Fl)
were infected with Ad-Cre and treated with DMSO or 3 μM 233 (C) or 3
μM 898 (D) as described for panels A-B. Western analysis of H4K5ac and
H4 was performed with whole cell lysates. For each treatment, signals for
H4K5ac were normalized to the signals for H4 (loading control).
Normalized signals for H4K5ac obtained from two independent
experiments are shown.
Additional file 6: Figure S6. Inhibition of Hdac1,2 activities for 24 h or
knockdown of Hdac1,2 for 72 h does not affect the cell cycle. A and B.
FACS analysis of Propidium iodide (PI) stained NIH3T3 cells treated with
DMSO or 3 μM 898 (A) or 3 μM 233 (B) for 24 h. C. FACS analysis of
Propidium iodide (PI) stained NIH3T3 cells transfected with either non-
targeting (NT) or Hdac1,2 siRNA transfected cells at 72 h time point
following transfection. Data shown is a representative of two
independent experiments.
Additional file 7: Figure S7. Inhibition of Hdac1,2 activities with 233
does not affect S-phase progression. Serum-starved NIH3T3 cells were
released into S-phase in the presence of DMSO or 3 μM 233. FACS
analysis following BrdU-propidium iodide labeling and staining of cellswas performed at 0 h, 12 h, 18 h and 24 h time points following release
into S-phase.
Additional file 8: Figure S8. Prolonged treatment of NIH3T3 cells with
898 causes a G1 arrest. A. FACS analysis following propidium iodide
staining of NIH3T3 cells was performed at 24 h and 48 h time points
following treatment with DMSO or 3 μM 898. B. FACS analysis of BrdU-
propidium iodide stained cells following 24 h or 48 h treatment with
3 μM 898. Percentage of BrdU-positive S-phase cells is indicated.
Additional file 9: Figure S9. BrdU incorporation is reduced following
treatment with 233. Slot blot analysis of BrdU-labeled genomic DNA
following treatment with 233 was performed using the indicated
amounts of purified DNA. For quantitation, BrdU incorporation in various
samples was measured using densitometry. Average BrdU incorporation
from three independent experiments are shown.
Additional file 10: Figure S10. Replication fork velocity is affected
following treatment with Hdac1,2-selective inhibitors or knockdown of
Hdacs1,2. DNA combing to measure replication fork velocity in NIH3T3
cells was performed 20 h following release into S-phase from serum
starvation in the presence of DMSO or 3 μM 898 (A) or following siRNA
knockdown of Hdacs1,2 (B). Cells were labeled with IdU (green) for
15 min and then with CldU (red) in the presence of 250 μM hydroxyurea
for 20 min. DNA fibers were prepared and analyzed as described in the
Methods section. Data represent average fork velocity of DNA fibers
prepared from four independent experiments with 898 treatment or
3 independent experiments with 233. Data from one knockdown
experiment is shown in the figure and the analysis was repeated twice. In
each experiment, at least 100 fibers in different areas of the slide from
three different slide preparations were analyzed. Error bars, standard error
of the mean from independent experiments. Box plot representation of
these data is shown in Figure 2C and 2D.
Additional file 11: Figure S11. Replication fork velocity is reduced
upon treatment with SAHA. A. NIH3T3 cells were treated with either
DMSO or 10 μM SAHA for 24 h. Fibers were prepared and analyzed as
described earlier in the methods section. Box-plot analysis was done with
data obtained from two independent experiments. B. Percentage fibers
with varying velocities are shown in panel B. Graph shows data from a
representative experiment. In each experiment, at least 100 fibers in
different areas of the slide from three different slide preparations were
analyzed.
Additional file 12: Figure S12. Quantitation of γH2AX foci in NIH3T3
cells following treatment with 3 μM 898 or 3 μM 233 for 48 hr. Cells with
various amount of big and bright foci in a population of 100 cells were
counted. Average percent of cells for each category obtained from four
independent experiments is shown. Representative immunofluorescence
image of γH2AX foci in the nuclei of control and Hdac1,2 inhibitor-
treated cells is shown in Figure 3A.
Additional file 13: Figure S13. DNA damage response is activated
following knockdown of Hdacs1,2. DNA damage in non-targeting (NT)
siRNA or Hdacs1,2-siRNA transfected NIH3T3 cells was measured at 72 h
time point by immunofluorescence analysis by staining for γH2AX.
Hoechst staining was performed to visualize nuclei. Cells with >5 γH2AX
foci in a population of 100 cells were counted. Average of two
independent experiments is shown.
Additional file 14: Figure S14. DNA damage response is activated in
primary mouse embryo fibroblast cells following 898 or 233
treatment. Wild-type mouse embryo fibroblasts (MEF) isolated from
13.5 (p.c.) embryos were treated with 3 μM 898 or 3 μM 233 for
48 hr. Immunofluorescence of γH2AX was performed and percentage
of cells with big bright foci were determined in two independent
experiments. Majority of cells had 1–5 foci. Data represents average
number of cells with γH2AX foci obtained from two different MEF
preparations.
Additional file 15: Figure S15. Quantitation of Rad51 foci formed in
S-phase cells following inhibition of Hdacs1,2. Serum-starved NIH3T3 cells
were released into S-phase and treated with either DMSO or 3 μM 233 or
3 μM 898 in the presence of 500 μM hydroxyurea. Immunofluorescence
staining for Rad51 was performed and percentage of cells with greater
than 5 foci were determined from two independent experiments, with
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immunofluorescence images with Rad51 foci are shown in Figure 3B.
Additional file 16: Figure S16. Inhibition of Hdac1,2 activities in
S-phase cells does not alter expression of genes coding for replication-
associated factors. Serum-starved NIH3T3s were released into S-phase in
the presence of DMSO or 3 μM 898 for 20 h. Three independent DMSO
and 898 treatments were performed for total RNA isolation. Purified RNA
was subjected to RNA-seq analyses. A. Four genes that were consistently
up-regulated in all three 898 treated samples compared to the DMSO
control. B. Levels of DNA damage-associated genes (ATM, Rad21) and
replication-associated genes (MCM2, CTPS, RPA1, RPA2, DNA polymerase
γ (Polg) and SMARCAD1) remain unchanged in all the three 898-treated
samples compared to DMSO control.
Additional file 17: Table S1. List of genes that are differentially
expressed in S-phase NIH3T3 cells following 3 μM 898 treatment.
Additional file 18: Figure S17. Hdacs1,2 do not target Smc3
acetylation. A. Chromatin from serum-starved NIH3T3 cells that were
released into S-phase in the presence of DMSO or 3 μM 898 for 0 h, 12 h,
18 h and 24 h was prepared for western analysis. Smc3 levels serve as
the loading control. B. NIH3T3 cells were transfected with either non-
targeting (NT) or Hdac1,2 (H12) siRNA prior to chromatin extract
preparation, and levels of Smc3ac and Smc3 were examined using
western analysis.
Additional file 19: Figure S18. Inhibition of Hdac1,2 activities increases
histone acetylation in S-phase cells. Quantitation of the western blot
performed with pan-acetyllysine (pan-AcK) antibody shown in Figure 5B.
Chromatin was prepared from NIH3T3 cells following release of cells into
S-phase from serum starvation and western blot analysis with pan-AcK
antibody was done to look at histone acetylation. Signals obtained for
histones H3, H2A, H2B and H4 were measured by densitometry. Data
represents cumulative signal for all four histones and the average signal
for histone +/− standard error from three independent experiments is
shown.
Additional file 20: Figure S19. Loss of Hdacs1,2 increases H4K16ac on
nascent chromatin. ChIP of H4K16ac was done and increasing volumes of
ChIP DNA were spotted onto a membrane using Slot Blot and probed
with anti-BrdU antibody. In A-B, a representative blot shown and the
experiment with 3.75 μM Hdac1,2 inhibitor and siRNAs was repeated at
least 3 times. Average BrdU signal of high and medium volume of ChIP
DNA spotted on the slot was quantified by the Image J software and is
shown on the right hand side of the figure.
Additional file 21: Figure S20. Knockdown of SMARCA5 reduces
replication fork velocity. Replication fork velocity was measured in HeLa
cells transfected with either non-targeting siRNA (NTsi) or SMARCA5
siRNA at 72 h time point following transfection. Data represent average
fork velocity calculated from three independent experiments. Error bars,
standard error of the mean.
Additional file 22: Figure S21. DNA damage response is activated in
HeLa cells following knockdown of SMARCA5. A. HeLa cells were
transfected with non-targeting (NT) or SMARCA5 siRNA and
immunofluorescence was performed to measure γH2AX foci formation. A.
Quantitation of percentage of cells with γH2AX foci in control (non-
targeting siRNA transfected) or SMARCA5 siRNA transfected cells in the
absence of hydroxyurea (HU) is shown in the left panel and cells with
pan-nuclear γH2AX staining in control (non-targeting siRNA transfected)
or SMARCA5 siRNA transfected cells in the presence of hydroxyurea (HU)
is shown in the right panel. Average data from two independent siRNA
transfections are shown. B. Representative images for pan-nuclear γH2AX
staining in control (non-targeting siRNA-transfected) or SMARCA5 siRNA-
transfected cells in the presence of hydroxyurea are shown.
Additional file 23: Table S2. Details of the antibodies used in this
study are listed in the supplementary table.
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